Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics
Shots:
- Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial milestones along with royalties on net sales of any products
- The collaboration will combine Metagenomis CRISPR-based & other novel gene editing systems with Modernas mRNA and LNP technologies to advance the development of in vivo gene editing therapeutics for the treatment of patients with serious genetic diseases
- Additionally, both companies will advance a series of in vivo gene editing therapeutics against undisclosed targets while Moderna focuses is to developing mRNA-based medicines
| Ref: Businesswire | Image: Moderna
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com